Medpace Holdings, Inc. (MEDP)
NASDAQ: MEDP · Real-Time Price · USD
462.50
+3.21 (0.70%)
Aug 13, 2025, 9:46 AM - Market open

Company Description

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia.

The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas.

It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.

In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials.

Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.

Medpace Holdings, Inc.
Medpace Holdings logo
CountryUnited States
Founded1992
IPO DateAug 11, 2016
IndustryDiagnostics & Research
SectorHealthcare
Employees5,900
CEOAugust Troendle

Contact Details

Address:
5375 Medpace Way
Cincinnati, Ohio 45227
United States
Phone(513) 579-9911
Websitemedpace.com

Stock Details

Ticker SymbolMEDP
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001668397
CUSIP Number58506Q109
ISIN NumberUS58506Q1094
Employer ID32-0434904
SIC Code8731

Key Executives

NamePosition
Dr. August James Troendle M.D.Chairman and Chief Executive Officer
Jesse J. Geiger BBA, CPAPresident
Kevin M. BradyChief Financial Officer and Treasurer
Susan E. Burwig BSN, MAExecutive Vice President of Operations
Stephen P. Ewald J.D.Chief Compliance Officer, General Counsel and Corporate Secretary
Brandon EbkenChief Information Officer
Lauren MorrisAssociate Director of Investors Relations
Todd MeyersVice President of Business Development and Marketing
Weimin Gai MSSenior Vice President of Biometrics
John T. Wynne MBASenior Vice President of Commercial Operations and Clinical Pharmacology Unit

Latest SEC Filings

DateTypeTitle
Jul 28, 2025144Filing
Jul 28, 2025144Filing
Jul 28, 2025144Filing
Jul 24, 2025144Filing
Jul 24, 2025144Filing
Jul 22, 202510-QQuarterly Report
Jul 21, 20258-KCurrent Report
May 16, 20258-KCurrent Report
Apr 24, 2025144Filing
Apr 22, 202510-QQuarterly Report